https://www.selleckchem.com/products/tp-0903.html
Vantictumab is a monoclonal antibody that binds to frizzled (FZD) receptors and inhibits canonical WNT signaling. This phase Ib dose escalation study enrolled patients with locally recurrent or metastatic HER2-negative breast cancer who were treated with weekly paclitaxel in combination with escalating doses of vantictumab. Patients were enrolled in dose escalation cohorts treated with weekly paclitaxel 90mg/m on days 1, 8 and 15 in combination with vantictumab 3.5-14mg/kg days 1 and 15 or 3-8mg/kg day 1 of every 28-day cycle. Primary e
Like
Comment
Share
